1 |
Miettinen, O. and Nurminen, M. (1985). Comparative analysis of two rates, Statistics in Medicine, 4, 213-226.
DOI
ScienceOn
|
2 |
Nauta, J. (2006). Statistical analysis of influenza vaccine lot consistency studies, Journal of Biopharma- ceutical Statistics, 16, 443-452.
|
3 |
Peduzzi, P., Donta, S. and Iwane, M. (1997). A Review of the design of vaccine efficacy trials and a proposal for the Design of the VA Cooperative study of active immunotherapy of HIV infection, Controlled Clinical Trials, 18, 397-419.
DOI
ScienceOn
|
4 |
한국과학기술정보연구원 (2006). <국가필수예방백신의 안정적공급을 위한 국가적 관리체계 구축>, 식품의약품안전청 연구보고서.
|
5 |
Chan, I. S. F., Bohidar, N. R. (1998). Exact power and sample size for vaccine efficacy studies, Communi- cations in Statistics Part A-Theory Methods, 27, 1305-1322.
DOI
ScienceOn
|
6 |
Ewell, M. (1996). Comparing methods for calculating confidence intervals for vaccine efficacy, Statistics in Medicine, 15, 2379-2392.
DOI
ScienceOn
|
7 |
FDA (2010). Guidance for Industry Non-inferiority clinical trials, Draft guidance
|
8 |
Gilbert, P. B. (2000). Some statistical issues in the design of HIV-1 vaccine an treatment trials, Statistical Methods in Medical Research, 9, 207-229.
DOI
|
9 |
Horne, A. D., Lachenbruch, P. A., Geston, P. R. and Hsu, H. S. (2001a). Analysis of studies to evaluate immune response to combination vaccines, Clinical Infectious Disease, 33, S306-311.
DOI
ScienceOn
|
10 |
Gilbert, P. B. (2010). Some design issues in phase 2B vs pahse 3 prevention trials for testing efficacy of products or concepts, Statistics in Medicine, 29, 1061-1071.
DOI
ScienceOn
|
11 |
Horne, A. D., Lachenbruch, P. A. and Goldenthal, K. L. (2001b). Intent-to-treat analysis and preventive vaccine efficacy, Vaccine, 19, 319-326.
|
12 |
Jovanovic, B. D. and Levy, P. S. (1997). A look at the rule of three, The American Statistician, 51, 137-139.
DOI
|
13 |
Lachenbruch, P. A. (1998). Sensitivity, specificity, and vaccine efficacy, Controlled Clinical Trials, 19, 569- 574.
DOI
ScienceOn
|
14 |
Lydia, A. F., Arciniega, J. and McVittie, L. (2001). Manufacturing issue with combining different antigens: A regulatory perspective, Clinical Infectious Diseases, 33, 351-355.
DOI
ScienceOn
|
15 |
식품의약품안전청 (2006). <백신의 임상평가시 고려사항>, 식품의약품안전청.
|
16 |
강승호 (2002). 정확검정들에 대한 고찰, <응용통계연구>, 15, 187-199.
DOI
|
17 |
강승호 (2010). <신약개발에 필요한 의학통계학>, 자유아카데미.
|
18 |
식품의약품안전청 <백신.BT정보방>, 식품의약품안전청.
|
19 |
식품의약품안전청 (2007). <백신의 임상평가시 고려사항 2007>, 식품의약품안전청.
|
20 |
식품의약품안전청 (2009a). <백신안전사용을 위한 핸드북>, 식품의약품안전청.
|
21 |
식품의약품안전청 (2009b). <약무행정(허가.심사) 용어해설집>, 식품의약품안전청.
|